Equities

Daxor Corp

Daxor Corp

Actions
  • Price (EUR)8.80
  • Today's Change0.20 / 2.33%
  • Shares traded10.00
  • 1 Year change-8.81%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.

  • Revenue in USD (TTM)163.42k
  • Net income in USD280.64k
  • Incorporated1971
  • Employees37.00
  • Location
    Daxor CorpSUITE 7120, 350 FIFTH AVENUENEW YORK 10118United StatesUSA
  • Phone+1 (212) 244-0555
  • Fax+1 (212) 244-0806
  • Websitehttps://www.daxor.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.